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Abstract: Elastin is considered as a key player in human vascular diseases and it might contribute to the develop-
ment of atherosclerosis. The elastin binding radiotracer, [18F]AlF-NOTA-EBM ([18F]2), was evaluated in a wild type 
mouse to determine its in vivo distribution and on human carotid atherosclerotic plaque tissues to assess its utility 
as a PET imaging agent for visualizing human atherosclerotic plaque lesions. The free ligand NOTA-EBM, which 
served as the precursor, was obtained in 25% chemical yield. The radiosynthesis of [18F]2 was accomplished by co-
ordination of Al18F to NOTA-EBM in 8-13% decay corrected radiochemical yield (n = 7) and specific radioactivity of 59 
± 12 GBq/µmol. A dynamic in vivo PET scan in a healthy wild type mouse (C57BL/6) showed high accumulation of 
radioactivity in heart and lungs, organs reported to have high elastin content. Excretion of [18F]2 proceeded via the 
renal pathway and through the hepatobiliary system as indicated by a high uptake of radioactivity in the liver, intes-
tines and gall bladder. In vitro autoradiography on human atherosclerotic plaque sections showed a heterogeneous 
distribution of [18F]2 with an elevated accumulation in stable and vulnerable atherosclerotic plaques compared to 
control samples of normal arteries. However, there was no statistical significance between the different plaque phe-
notypes and control samples. Competition experiments with 10.000-fold excess of free ligand NOTA-EBM resulted 
in a marked decrease of radioactivity accumulation, consistent with a target-specific ligand.
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Introduction
Cardiovascular disease (CD) is currently the 
most frequent cause of death and illness in 
industrial countries and the prognosis of the 
World Health Organization (WHO) is that CD will 
soon become the leading health problem world-
wide [1]. Atherosclerosis, an inflammatory dis-
ease characterized by the accumulation of lip-
ids and fibrous elements in the intima of the 
artery walls, plays a key role in the pathogene-
sis of cardiovascular diseases. Myocardial 
infarction or stroke can result from expansion 
and destabilization of atherosclerotic lesions, 
leading to plaque rupture and subsequent 
thrombotic events [2-5]. Prevention of serious 
cardiovascular events has therefore been 
linked to early diagnosis and detection of ath-
erosclerotic lesions. In the last years, much 
effort has been put on various non-invasive 
imaging techniques to detect the presence of 
plaque lesions. Imaging modalities such as 
ultrasound, computed tomography (CT), mag-
netic resonance imaging (MRI) and nuclear 
imaging methods like single photon computed 
tomography (SPECT) and positron emission 
tomography (PET) provide information with 
diagnostic and prognostic value but each imag-
ing approach presents advantages and weak-
nesses [6-11]. A foremost advantage of nuclear 
imaging is the excellent sensitivity and adminis-
tration of only low mass doses resulting in pico-
molar levels at the target site compared with 
MRI and CT, where higher mass doses (10-3 - 
10-5 M) of contrast agent are used [12, 13]. 
The extracellular matrix (ECM) plays a critical 
role during the development of atherosclerosis 
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providing the structural integrity of the plaques 
and participating in several key events to regu-
late cell function [14, 15]. Degradation of the 
ECM can lead to plaque instability and subse-
quent plaque rupture, whereas enhanced syn-
thesis of the ECM leads to vessel wall remodel-
ling and contributes to plaque stabilization [14]. 
The structural protein elastin is the dominant 
extracellular matrix protein deposited in the 
arterial wall and can contribute up to 50% of its 
dry weight [16]. Elastin is the main component 
of elastic fibers, which provides elasticity and 
resilience to many tissues such as skin, lungs, 
ligaments and arterial walls [15, 17]. It is known 
that smooth muscle cells are the elastin-pro-
ducing cells in plaques [14, 15, 18]. As an addi-
tional source for this matrix protein, Krettek et 
al. identified human macrophages within 
plaques producing the elastin precursor tropo-
elastin [19]. Therefore, elastin is considered as 
a key player in human vascular diseases and it 
might contribute to the development of athero-
sclerosis [20]. 
A recent study published by Makowski and co-
workers showed that atherosclerotic plaque 
burden in an ApoE-/- mouse model could be 
imaged with an elastin-specific MRI contrast 
agent ESMA (1, Figure 1) [21]. Quantitative 
changes of the plaque matrix elastin content at 
various stages of atherosclerosis in compari-
son to healthy arteries were visualized through 
signal intensity measurements. In vivo compe-
tition experiments with non-paramagnetic 
ESMA resulted in a marked decrease of the sig-
nal, consistent with a target-specific contrast 
agent. Electron microscopy studies also 
showed a marked co-localization of ESMA with 
elastic fibers [21].
These encouraging results prompted us to 
investigate whether an ESMA-based PET radio-
ligand can be used to image atherosclerotic 
plaques. Consequently, we modified ESMA with 
a macrocyclic chelator, 1,4,7-triazacyclonon-
ane-1,4,7-triacetic acid (NOTA), such that the 
resulting elastin binding molecule (EBM) is 
amenable to radiolabeling with a positron emit-
ting radionuclide. NOTA is a suitable chelator 
that is known to form stable complexes with 
various radionuclides such as 68Ga, 64Cu and 
Al18F [22, 23]. 
In this work, we report a proof of concept study 
with the Al18F-labeled NOTA-coupled elastin 
binding molecule, [18F]AlF-NOTA-EBM ([18F]2, 
Figure 1). 
This novel radiotracer was evaluated in a wild 
type mouse (C57BL/6) to determine its in vivo 
distribution and in vitro on human carotid ath-
erosclerotic plaque sections to assess its 
potential for imaging atherosclerotic plaque 
lesions. 
Material and methods
General
Reagents and solvents were purchased from 
Sigma-Aldrich, Merck AG, VWR International AG 
or Bachem. All chemicals were used as sup-
plied unless stated otherwise. Low resolution 
mass spectra (LRMS) were recorded with a 
Micromass Quattro micro API LC-ESI and high 
resolution mass spectra (HRMS) with a Bruker 
FTMS 4.7 T BioAPEXII spectrometer (ESI). 
Nuclear magnetic resonance spectra were 
recorded on a Bruker 400 MHz spectrometer 
with the corresponding solvent signals as an 
internal standard. Chemical shifts are reported 
Figure 1. Chemical structures of the gadolinium-con-
taining elastin-specific MRI contrast agent [158Gd]-
ESMA (1) and the novel Al18F-labeled NOTA-coupled 
elastin binding molecule [18F]AlF-NOTA-EBM ([18F]2). 
The elastin binding part is highlighted in red. 
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in parts per million (ppm) relative to tetrameth-
ylsilane (0.00 ppm). Values of the coupling con-
stant, J, are given in hertz (Hz); the following 
abbreviations are used in the experimental sec-
tion for the description of 1H-NMR spectra: sin-
glet (s), doublet (d), triplet (t) and multiplet (m). 
Reactions were monitored by thin layer chroma-
tography (TLC, performed on Merck precoated 
silica gel 60 F-254 aluminium plates) or high 
performance liquid chromatography (HPLC). 
HPLC was performed on a Merck-Hitachi L7000 
system equipped with a L7400 tunable absorp-
tion detector. Analytical HPLC was performed 
with a reversed-phase column (Gemini-NX C18, 
5 μm, 4.6 × 250 mm, Phenomenex) using 0.1% 
TFA in water (solvent A) and acetonitrile (solvent 
B) as a solvent system with a gradient from 0 - 
12 min 85% A, 12 - 17 min 85 - 30% A, 17 - 25 
min 30% A and a flow rate of 1 mL/min. 
Preparative HPLC was performed with a 
reversed-phase preparative column (UltisilTM 
former Ultimate C18, 5 μm, 21.2 × 150 mm, 
Welch Materials) at a flow rate of 18 mL/min 
with 0.1% TFA in water (solvent A) and acetoni-
trile (solvent B) as solvent system and a gradi-
ent as follows: 0 - 20 min 100 - 70% A, 20 - 28 
min 70 - 30% A, 28 - 34 min 30% 
A. Analytical radio-HPLC was per-
formed on a Merck-Hitachi 
L2130 system equipped with a 
L2450 diode array detector and 
a Berthold radiodetector with a 
reversed-phase column (Gemini 
C18-NX, 5 μm, 4.6 × 250 mm, 
Phenomenex) using 0.1% TFA in 
water (solvent A) and acetonitrile 
(solvent B) as solvent system 
with a gradient from 0 - 16 min 
85% A, 16 - 22 min 85 - 30% A, 
22 - 30 min 30% A and a flow rate 
of 1 mL/min. Semi-preparative 
radio-HPLC was performed on a 
HPLC system equipped with a 
Merck-Hitachi L6200A intelligent 
pump, a Knauer variable-wave-
length ultraviolet detector and an 
Eberline RM14 radiodetector. 
[18F]2 was purified on a reversed-
phase semi-preparative column 
(Gemini C18, 5 µm, 250 x 10 
mm, Phenomenex) at a flow rate 
of 4 mL/min with 0.1% TFA in 
water (solvent A) and acetonitrile 
(solvent B) as solvent system and 
Figure 2. Synthesis of the free ligand 2 from key intermediate 4 via cou-
pling reaction with protected NOTA derivative 3.
a gradient as follows: 0 - 3 min 100% A, 3 - 4 
min 100 - 85% A, 4 - 20 min 85% A, 20 - 26 min 
85 - 30% A, 26 - 40 min 30% A.
Specific radioactivity was determined by ana-
lytical radio-HPLC from a calibration curve 
obtained from different concentrations of the 
free ligand 2.
Synthesis of free ligand NOTA-EBM (2) 
The synthesis of the free ligand 2 from key 
intermediate 4 via coupling reaction with NOTA 
derivative 3 is illustrated in Figure 2. Key inter-
mediate 4 was prepared according to a pub-
lished patent [24] in analogy to the elastin-spe-
cific MRI contrast agent ESMA (BMS753951) 
reported by Makowski et al. [21].
To a solution of NOTA(tBu)2 (3, 199.5 mg, 0.48 
mmol) in acetonitrile (10 mL) HBTU (182.6 mg, 
0.48 mmol), HOBt (65.4 mg, 0.48 mmol) and 
Et3N (0.27 mL, 1.92 mmol) were added. 
Compound 4 (245.8 mg, 0.58 mmol) was dis-
solved in acetonitrile (2 mL) and added to the 
reaction mixture in one portion. Thereafter, the 
solution was stirred at ambient temperature for 
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14 h and then concentrated in vacuo. The resi-
due was dissolved in ethylacetate (50 mL) and 
washed with 10% aqueous citric acid (3 × 25 
mL), sat. aqueous NaHCO3-solution (3 × 25 mL) 
and brine (25 mL). After drying over Na2SO4, the 
solution was concentrated under reduced pres-
sure and the protected NOTA derivative was 
used for the next step without further purifica-
tion. LR-MS (ES+) calculated for C43H65N7O9: 
825.02; found: 825.67.
For deprotection, the protected NOTA derivative 
was dissolved in acetonitrile (5 mL) and TFA (5 
mL) and stirred 24 h at ambient temperature. 
The reaction progress was monitored by HPLC. 
For isolation of the product, the mixture was 
submitted to preparative HPLC. The desired fra- 
ction was collected and lyophilized to provided 
product 2 as a white powder (73 mg, 25% over 
two steps, purity according to HPLC > 86%).
1H-NMR (DMSO-d6) δ/ppm 2.14 (m, 2H), 2.82 
(m, 2H), 3.05 (m, 12H), 3.68 (s, 4H), 3.85 (s, 
2H), 4.07 (m, 1H), 4.44 (d, J = 5.9 Hz, 2H), 7.28 
(m, 2H), 7.37 (t, J = 7.5 Hz, 2H), 7.48 (m, 3H), 
7.92 (m, 2H), 8.47 (s, 2H), 8.81 (t, J = 5.9 Hz, 
1H), 10.61 (d, J = 12.8 Hz, 2H); HRMS (ES+) cal-
culated for C30H42N7O7: 612.3140; found: 
612.3139.
Radiochemistry
No-carrier-added [18F]fluoride was produced via 
the 18O(p,n)18F nuclear reaction at a Cyclone 
18/9 cyclotron (IBA, Belgium) by irradiation of 
enriched 18O-water. [18F]fluoride was immobi-
lized on an anion-exchange cartridge (QMA 
Light; Waters; preconditioned with 0.5 M 
CH3COONa-solution (5 mL, pH 8.8) and H2O (5 
- 10 mL)) and eluted with 0.9% NaCl-solution. 
[18F]fluoride (ca. 15 GBq) in ca. 50 µL saline 
was mixed with 80 µL free ligand solution 2 (2 
mM, 160 nmol) in 0.1 M NaOAc (pH 4) and 40 
µL AlCl3 solution (2 mM, 80 nmol) in 0.1 M 
NaOAc (pH 4) in a 5 mL sealed reaction vessel. 
The reaction mixture was incubated at 105°C 
for 15 min. After cooling for 5 min, 4 mL of 
water was added to the reactive vial and the 
mixture was purified by semi-preparative radio-
HPLC. The product fraction was collected into 
20 mL of water and the mixture was passed 
through a reversed-phase cartridge (Sep-Pak 
C18 light; Waters; preconditioned with EtOH (5 
mL) and H2O (5 mL)) to remove acetonitrile. The 
cartridge was washed with 10 mL of water and 
the 18F-labeled product [18F]2 was eluted with 
0.5 mL of ethanol into a sterile, pyrogen-free 
vial and diluted with 5 mL water for stability 
studies. Samples of [18F]2 were taken at differ-
ent time points and analyzed by analytical 
radio-HPLC. For PET imaging studies, the solu-
tion of [18F]2 in water was diluted with 4.5 mL of 
0.9% NaCl-solution, whereas for in vitro autora-
diography studies, [18F]2 was diluted with TRIS 
buffer (50 mM Tris, 150 mM NaCl, pH 7.4) to a 
final radiotracer concentration of 50 nM.
Determination of distribution coefficient 
The distribution coefficient (logD7.4) was deter-
mined by the shake flask method. In brief, [18F]2 
was dissolved in a mixture of phosphate buffer 
(500 µL, pH 7.4) and n-octanol (500 µL) at 
20°C. Thereafter, the sample was equilibrated 
for 15 min in an over-head shaker and the two 
phases were separated by centrifugation (3 
min, 5000 rpm). Aliquots (50 µL) of both phas-
es were analyzed in a γ-counter (Wizard, 
PerkinElmer). The partition coefficient was 
expressed as the ratio between the radioactiv-
ity concentrations (cpm/mL) of the n-octanol 
and the buffer phase. Values represent the 
mean ± standard deviation of eight determina-
tions from two independent experiments. 
In vivo PET imaging studies 
Five-week-old male C57BL/6 mice were 
obtained from Charles River (Germany). Animal 
care and all experimental procedures were 
approved by Cantonal Veterinary Office in 
Zurich, Switzerland. Animals had free excess to 
food and water. PET experiments were per-
formed with an eXplore VISTA PET/CT tomo-
graph (Sedecal, Spain/GE Healthcare) with a 
maximum resolution of 2 mm full width at half 
maximum [25]. Anesthesia was induced with 
isoflurane in an air/oxygen mixture and one ani-
mal was injected with 13 MBq (4.2 nmol) of 
[18F]2 via a lateral tail vein. A dynamic PET scan 
was acquired from 0 - 90 min post injection 
(p.i.). After acquisition, PET data were recon-
structed in user-defined time frames and fused 
datasets of PET and CT were analyzed with 
PMOD software (version 3.4).
Human carotid atherosclerotic tissue bank
This study was conducted with excised tissue 
from 25 patients referred to the clinic for car-
Atherosclerotic plaque imaging with an elastin binding molecule
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diovascular surgery of the University Hospital of 
Zurich for carotid endarterectomy (CEA). 
Written informed consent was obtained from 
all patients. The atherosclerotic plaques were 
removed from the internal, common or external 
carotid artery as previously described [26]. 
After dissection, the tissues were immediately 
frozen and stored at 80°C until sectioned. 
According to the classification of the American 
Heart Association, plaques were characterized 
as stable if they macroscopically presented a 
lipid core encapsulated between a fibrous cap 
and the media without endothelial disruption. 
Plaques were considered vulnerable if there 
was intraplaque hemorrhage evolving in the 
necrotic core, disruption of the surface or 
thrombosis [27, 28]. These macroscopic fea-
tures of vulnerable plaques or the presence of 
the intact fibrous cap in stable plaques were 
confirmed by histological analysis such as 
hematoxylin and eosin and Masson Goldner’s 
trichrom staining (data not shown). The micro-
scopic classification was in agreement with the 
macroscopic classification. Furthermore, for 
division into vulnerable plaques, the threshold 
of the representative cap thickness was con-
sidered to be < 500 µm and of the minimum 
cap thickness < 200 µm in carotid plaques 
[29]. In this study, human tissue samples of vul-
nerable plaques, stable plaques and samples 
of normal artery walls as controls were used. 
Table 1 summarizes the characteristics of the 
patients in this study.
Hearts from 6-week-old Wistar rats (Charles 
River, Germany) were used as positive control 
and internal standard. 
In vitro autoradiography studies 
Frozen transversal slices (20 μm) adsorbed to 
SuperFrost Plus slides were thawed at ambient 
temperature and preincubated on ice for 15 
min in TRIS buffer (50 mM Tris, 150 mM NaCl, 
pH 7.4 at 4°C) containing 0.1% bovine serum 
albumin (BSA). Excess solution was carefully 
removed, and slides were incubated with 50 
nM [18F]2 alone or together with 500 µM 2 in 
TRIS buffer for 45 min at ambient temperature. 
After incubation, the solutions were decanted 
and the slides washed in TRIS buffer containing 
0.1% BSA (5 min), three times in TRIS buffer (5 
min each) and finally dipped twice in distilled 
water, all steps at 4°C. To generate a calibra-
tion curve, a dilution series of the radiotracer 
[18F]2 was prepared and pipetted on filter 
papers. Dried slides and filter papers were 
exposed to the same phosphor imager plate 
(BAS-MS 2025, Fuji) for 15 min, and the plate 
was scanned in a BAS5000 reader (Fuji). 
Quantitative examination was performed with 
the AIDA evaluation software. The maximum 
intensity of each tissue section was deter-
mined, the background was subtracted and the 
amount of radiotracer bound to the tissue was 
calculated using the calibration curve. All 
patient samples were normalized to values 
from the rat heart whereby the maximal bound 
radiotracer was set to 1. Afterwards, the sec-
tions were stained by hematoxylin and eosin.
Statistical analysis 
Statistical analyses were performed by using 
the unpaired two-tailed Student’s t-test (Graph 
Pad Prism 6.0 software). A P-value of ≤ 0.05 
was considered statistically significant.
Results 
Chemistry and radiochemistry 
The synthesis of key intermediate 4 was accom-
plished in 49% chemical yield according to the 
procedure published by Harris et al. [24]. 
Intermediate 4 was coupled to commercially 
available NOTA derivative 3 using HBTU as a 
coupling reagent [30] (Figure 2). The protected 
NOTA-EBM derivative was used for the next 
step without further purification. After deprot-
ection of the Boc-group with TFA and purifica-
tion by HPLC, precursor compound 2 was 
obtained as a white solid in 25% chemical yield. 
The radiosynthesis of [18F]2 was performed in 
analogy to a previously published procedure 
[31, 32]. [18F]2 was accomplished by coordina-
tion of Al18F under slightly acidic conditions in 
20 - 25% incorporation yield. After HPLC-
Table 1. Characteristics of the patients in-
cluded in this study
Characteristics
Patients 25
Female/Men 2/23
Age at surgery (y) 72 ± 7
Normal arteries 7
Stable plaques 13
Vulnerable plaques 10
Data are mean ± SD or n.
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purification, the target compound was obtained 
in a decay-corrected radiochemical yield of 8 - 
13% (n = 7). Typically, starting from 10 - 15 GBq 
of [18F]-fluoride, 0.5 - 1.4 GBq of isolated prod-
uct were obtained after an overall synthesis 
time of ~1 h. The radiochemical purity of [18F]2 
was ≥ 95%, with a specific radioactivity (EOS) of 
59 ± 12 GBq/µmol. The logD7.4 value of [
18F]2 
was -1.3 ± 0.1 and stability studies of [18F]2 
revealed no defluorination or radioactive degra-
dation products within 120 min at room tem-
perature, which was confirmed by analytical 
radio-HPLC.
In vivo PET imaging 
A dynamic PET scan was performed with a wild 
type mouse to determine the in vivo distribu-
tion of [18F]2. Figure 3 shows a time series of 
coronal sections from the heart and neck 
region after [18F]2 application. Each section 
represents a 5 min time frame. 
In early time frames up to 15 min p.i., high 
accumulation of radioactivity was found in the 
carotid arteries and heart region. After approxi-
mately 15 min p.i. the accumulation of radioac-
tivity in the carotid arteries decreased, whereas 
uptake of [18F]2 remained high in heart and 
liver. Starting from 40 min p.i. a high accumula-
tion of radioactivity was observed in the gall 
bladder. 
In Figure 4 different coronal sections of [18F]2 
uptake averaged from 0 to 90 min p.i. are 
shown. High uptake of radioactivity was 
observed in the lungs and the heart, organs 
known to have high elastin content. 
Accumulation of [18F]2 was also visible in the 
animal skin and paws. Excretion organs such 
Figure 3. PET images showing coronal sections of a wild type mouse from 0 to 90 min acquisition after injection of 
13 MBq (4.2 nmol) of [18F]2. Each section represents a 5 min time frame (He: heart with *carotid arteries in the 
neck region, Li: liver, GB: gall bladder).
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as kidneys, liver, intestines and gall bladder 
showed a high uptake of radioactivity.
In vitro autoradiography studies 
Human carotid artery vessels with different 
plaque phenotypes or from normal arteries 
were used for in vitro 
autoradiography stud-
ies. A rat heart served 
as a positive control 
and as an internal stan-
dard for later quantifi-
cations. All human tis-
sue samples showed a 
heterogeneous accu-
mulation of [18F]2. Rat 
hearts showed general-
ly higher binding of the 
radiotracer than the 
patient samples (Figure 
5). Several hot spots of 
radioactivity were ob- 
served in atheroscle-
rotic plaque samples. 
With an 10.000-fold 
excess of the free 
ligand 2, accumulation 
of [18F]2 decreased in 
all tissue samples. 
In Figure 6 are depicted 
the normalized accu-
mulation values of the 
human tissue samples 
grouped according to 
their phenotype. There 
was a trend towards a 
higher accumulation of 
[18F]2 in stable and vul-
nerable atherosclerotic 
plaques but no statisti-
cal significance could 
be detected between 
samples of normal 
arteries and athero-
sclerotic plaques (nor-
mal arteries vs. stable 
plaques: P = 0.44; nor- 
mal arteries vs. vulne- 
rable plaques: P = 
0.15) as well as bet- 
ween both plaque phe- 
notypes (P = 0.55).
Figure 4. Different coronal slices of a PET image of a wild type mouse averaged 
from 0 to 90 min after injection of 13 MBq (4.2 nmol) of [18F]2 (Li: liver, Ki: kidneys, 
Lu: lungs, Int: intestines/feces, He: heart, GB: gall bladder, FP: front paws).
Figure 5. Representative examples of human atherosclerotic plaque and rat heart 
sections incubated with [18F]2 alone (first row) or with excess of the free ligand 2 
(middle row). The bottom row shows hematoxylin-eosin staining of the samples. 
Discussion
Imaging techniques currently being used in the 
clinic to identify atherosclerotic plaques include 
ultrasound, CT, MRI and nuclear imaging meth-
ods like SPECT and PET. Early detection of the 
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life-threatening vulnerable atherosclerotic 
plaques using one of these imaging modalities 
would be an important step towards patient 
care and management. So far, 2-deoxy-2-[18F]
fluoro-d-glucose [18F]FDG is the most common-
ly used radiotracer in the clinic for the PET 
imaging of atherosclerosis but is limited by its 
lack of cellular specificity [10]. As such, more 
specific radiotracers are needed.
In a recent study, Makowski and co-workers fol-
lowed the progression and regression of plaque 
burden in an ApoE-/- mouse model using the 
elastin-specific MRI contrast agent ESMA. 
Changes in the content of elastin in atheroscle-
rotic plaques in comparison to healthy arteries 
were demonstrated [21].
Our goal was to verify whether ESMA radiola-
beled with an appropriate PET radionuclide can 
be used to visualize plaque burden. To this end, 
we designed and prepared [18F]AlF-NOTA-EBM 
as a potential elastin binding PET radiotracer. 
Complexation reactions of Al18F with NOTA have 
recently being reported by a number of research 
groups [23, 31-36]. The reactions are generally 
efficient and afford stable compounds in opti-
mal radiochemical yields. We find it attractive 
to use this technique for the 18F-labeling of 
NOTA-EBM.
The synthesis of the precursor compound 2 
was achieved in a two-step procedure (Figure 
2). The coupling of the NOTA chelator to com-
pound 4, which was synthesized in good yields 
in analogy to a published procedure by Harris et 
al. [24], was accomplished using HBTU as a 
coupling reagent. After a deprotection step, 
compound 2 was obtained in 25% chemical 
yield. NMR spectroscopy and high resolution 
mass spectrometry confirmed the structure of 
NOTA-EBM. 
The radiosynthesis of [18F]2 was achieved in a 
decay corrected radiochemical yield of 8-13% 
(n = 7) and a specific radioactivity (EOS) of 59 ± 
12 GBq/µmol. Due to the formation of radiola-
beled by-products, purification by semi-prepar-
ative HPLC was necessary. Purification using 
cartridges was not possible due to the similar 
elution profile of [18F]2 and side-products. An 
explanation for the occurrence of by-products 
could be the moderate purity (> 86%) of the 
precursor, NOTA-EBM. 
In order to determine the in vivo behaviour and 
distribution of [18F]2, an in vivo PET scan in a 
wild type mouse was performed. This PET study 
showed that [18F]2 is excreted not only through 
the kidneys but also through the hepatobiliary 
system as indicated by a high uptake of [18F]2 
in the liver, intestines and gall bladder. The 
determined logD7.4 value of -1.3 ± 0.1 for [
18F]2 
suggested that the radiotracer is relatively 
hydrophilic and that its clearance may predomi-
nately proceed via the renal excretion pathway. 
[18F]2 was slowly cleared from the blood pool 
within the first 30 min after injection. For the 
imaging of carotid plaques, this would suggest 
later time points in order to achieve better tar-
get-to-background ratios. In general, a high 
uptake of the radiotracer [18F]2 was observed 
in organs such as lungs and heart, reported to 
have prominent elastin content [15, 17]. Similar 
high accumulation of [18F]2 was also observed 
to the animal skin and paws in the PET image 
corroborating literature data that paws and 
skin of rodents are also rich in elastic fibers, 
which are made of the structural protein elastin 
[17, 37]. 
Encouraged by the in vivo behavior of [18F]2, we 
performed in vitro autoradiography studies on 
human carotid plaque sections and found a 
heterogeneous accumulation of [18F]2 to phe-
notypically different plaque samples. Compared 
to all plaque samples, the rat heart showed the 
highest binding of [18F]2. Due to the known high 
Figure 6. Normalized data of [18F]2 accumulation in 
tissue sections obtained by in vitro autoradiography 
(rat heart as internal standard is set to 1). Athero-
sclerotic samples were grouped according to their 
phenotype. The lines represent the mean of each 
group.
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and evenly distribution of elastin in the rodent 
heart [15, 17], the rat heart served as an inter-
nal standard in this study. 
Competition experiments with 10.000-fold 
excess of free ligand 2 resulted in a marked 
decrease of radioactivity accumulation, sug-
gesting competition for the same binding sites. 
Compared to human control samples of normal 
arteries, a higher binding of [18F]2 was observed 
in stable and vulnerable atherosclerotic 
plaques, however, no clear differentiation 
between stable and vulnerable atherosclerotic 
plaques was evident. The higher uptake of 
[18F]2 in stable and vulnerable atherosclerotic 
plaques may be explained by the increased 
extracellular matrix remodelling in atheroscle-
rotic plaque progression and smooth muscle 
cell proliferation [14, 15, 18, 20]. 
Conclusions
The radiosynthesis of [18F]AlF-NOTA-EBM was 
accomplished in optimal radiochemical yields 
and high specific radioactivity. The novel elastin 
binding radiotracer [18F]2, exhibited high bind-
ing to organs with high elastin content. In vitro 
autoradiography studies using human athero-
sclerotic plaque tissues from carotid vessels, 
revealed higher accumulation of [18F]2 in 
plaque samples compared to control samples 
of normal arteries, however no statistical sig-
nificance was evident. [18F]AlF-NOTA-EBM might 
thus not be a useful imaging agent for visualiz-
ing atherosclerotic plaques in carotid arteries 
by PET.
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